Респираторная медицина. Руководство (в 2-х томах)
Шрифт:
78. Devillier P., Millart H., Advenier C. The anti-leukotrienes: their use in asthma. // Rev. Med. Brux.
– 1997 Sep.
– V. 18, 4.
– P. 279-285.
79. Drazen J.M. Pharmacology of leukotriene receptor antagonists and 5-lipoxigenase inhibitors in the management of asthma. // Pharmacotherapy.
– 1997 Jan.
– V. 17, 1 Pt 2.
– P. 22-30.
80. O'Byrne PM. Leukotrienes in the pathogenesis of asthma. Chest. 1997 Feb;111(2 Suppl):27S-34S
81. Felder CC. Muscarinic acetylcholine receptors: signal transduction through multiple effectors. FASEB J 1995;9:619 - 625.
82. Koumis T, Samuel S. Tiotropium bromide: a new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease. Clin Ther. 2005 Apr;27(4):377-92.
83. Somand H, Remington TL. Tiotropium: a bronchodilator for chronic obstructive pulmonary disease. Ann Pharmacother. 2005 Sep;39(9):1467-75. Epub 2005 Jul 19.
84. Proskocil BJ and Fryer AD
85. Liu J, Lester P, Builder S, et al. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 1995;34(33):10474 - 82.
86. Boushey H. Experiences with monoclonal antibody therapy for allergic asthma. J Allergy Clin Immunol 2001;108(2 Suppl):S79
87. Liu J, Lester P, Builder S, Shire SJ. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry. 1995;34:10474-10482.
88. Presta L, Shields R, O'Connell L, et al. The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem. 1994;269:26368-26373.
89. Sechi S, Roller PP, Willette-Brown J, Kinet JP. A conformational rearrangement upon binding of IgE to its high affinity receptor. J Biol Chem. 1996;271:19256-19263.
90. Chang TW. The pharmacological basis of anti-IgE therapy. Nat Biotechnol. 2000;18:157-162.
91. Shields RL, Whether WR, Zioncheck K, et al. Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol. 1995;107:308-312.
92. Schmidt D, Watson N, Reulmann E, Magnussen H, Rabe KF. Serum IgE levels predict human
93.airway reactivity in vitro. Clin Exp Allergy 2000;30(2):233 - 41.
94. Brownell J, Casale TB Anti-IgE therapy. Immunol Allergy Clin N Am 24 (2004) 551 - 568
95. Boulet LP, Chapman KR, Cote J, et al. Inhibitory effects of an anti-IgE antibody E25 on allergeninduced early asthmatic response. Am J Respir CritCare Med 1997;155(6):1835 - 40.
96. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108(2):184 - 90.
97. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children (Review). The Cochrane Library 2007, Issue 1
98. Nowak D. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab. Respir Med. 2006 Nov;100(11):1907-17. Epub 2006
99. Global Strategy for Asthma Management and Prevention. REVISED 2006. The GINA reports are available on www.ginasthma.org.
100. Genentech, Inc. Xolair(R) (omalizumab for subcutaneous use) package insert. South San Francisco, Calif; June 2003.
101. Marian M, Sun Y-N, Sinclair BS, et al. Clinical pharmacokinetics (PK) and IgE pharmacodynamics (PD) of omalizumab, a recombinant humanized monoclonal antibody to IgE. Clin Pharmacol Ther. 2001;69:P7.
102. Bisberg D, Froehlich J, Schoenhoff M, Mendelson J. Multiple administrations of the anti-IgE recombinant humanized monoclonal antibody E25 (rhuMAb-E25) reduces free IgE levels in a dose dependent manner in adolescents and children with moderate to severe allergic asthma. J Clin Pharmacol. 1996;36:859.
103. Schoenwetter W, Gupta N, Liu J, van As A. Omalizumab, an anti-immunoglobulin E antibody, is well tolerated in patients with allergic diseases of the airways [abstract]. Chest 2002; 122(4 Suppl):Abst P118.
104. Genentech, Inc. Prescribing information: summary of product characteristics. Available at: http://
105.www.xolair.com. Accessed January 3, 2003.
106. Guevara JP, Ducharme FM, Keren R, Nihtianova S, Zorc J. Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD003558.
107.
108. Davies J, Trindale M, Wallis C, Rosenthal M, Bush A. The clinical use of rhDNAse. Pediatr Pulmonol Suppl. 1997;16:273-4.
109. Greenfeder S, Umland SP, Cuss FM, et al. Th2 cytokines and asthma. The role of interleukin-5 in allergic eosinophilic disease. Respir Res 2001;2(2):71 - 9.
110. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness and the late asthmatic response. Lancet 2000;356(9248):2144 - 8.
111. Kay AB, Klion AD. Anti-interleukin-5 therapy for asthma and hypereosinophilic syndrome. Immunol Allergy Clin North Am 2004;24(4):645 - 66.
112. Steinke JW, Borish L. TH2 cytokines and asthma. Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists. Respir Res 2001;2(2):66 - 70.
113. Holgate ST. Cytokine and anti-cytokine therapy for thetreatment of asthma and allergic disease. Cytokine 2004;28(4 - 5):152 - 7.